MFDS Approves Rare Drug 'Zenpozyme Injection'
The Ministry of Food and Drug Safety announced on the 25th that it has approved 'Xenpozyme Injection (Olipudase Alfa),' a rare drug from Sanofi-Aventis Korea Co., Ltd., used to treat Acid Sphingomyelinase Deficiency (ASMD).
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Acid Sphingomyelinase Deficiency (ASMD) is a rare disease caused by decreased activity of acid sphingomyelinase, leading to the accumulation of sphingomyelin in the spleen, liver, lungs, bone marrow, and lymph nodes, resulting in hepatosplenomegaly and pulmonary disease. 'Xenpozyme Injection' is an acid sphingomyelinase produced using recombinant DNA technology, which, when administered to patients, reduces sphingomyelin accumulation in organs and alleviates symptoms.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
